Overview

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

Status:
Completed
Trial end date:
2018-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity of romidepsin in patients with progressive or relapsed peripheral T-cell lymphoma (PTCL) who have already been treated with systemic therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Romidepsin